Cargando…
Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study
BACKGROUND: Biologic therapies have revolutionized the treatment of moderate‐to‐severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. OBJECTIVES: To evaluate demographic, social and clinical factors that could be used to predict effecti...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519065/ https://www.ncbi.nlm.nih.gov/pubmed/30155885 http://dx.doi.org/10.1111/bjd.16776 |
_version_ | 1783418575765110784 |
---|---|
author | Warren, R.B. Marsden, A. Tomenson, B. Mason, K.J. Soliman, M.M. Burden, A.D. Reynolds, N.J. Stocken, D. Emsley, R. Griffiths, C.E.M. Smith, C. |
author_facet | Warren, R.B. Marsden, A. Tomenson, B. Mason, K.J. Soliman, M.M. Burden, A.D. Reynolds, N.J. Stocken, D. Emsley, R. Griffiths, C.E.M. Smith, C. |
author_sort | Warren, R.B. |
collection | PubMed |
description | BACKGROUND: Biologic therapies have revolutionized the treatment of moderate‐to‐severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. OBJECTIVES: To evaluate demographic, social and clinical factors that could be used to predict effectiveness and stratify response to biologic therapies in psoriasis. METHODS: Using a multicentre, observational, prospective pharmacovigilance study (BADBIR), we identified biologic‐naive patients starting biologics with outcome data at 6 (n = 3079) and 12 (n = 3110) months. Associations between 31 putative predictors and outcomes were investigated in univariate and multivariable regression analyses. Potential stratifiers of treatment response were investigated with statistical interactions. RESULTS: Eight factors associated with reduced odds of achieving ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90) at 6 months were identified (described as odds ratio and 95% confidence interval): demographic (female sex, 0·78, 0·66–0·93); social (unemployment, 0·67, 0·45–0·99); unemployment due to ill health (0·62, 0·48–0·82); ex‐ and current smoking (0·81, 0·66–0·99 and 0·79, 0·63–0·99, respectively); clinical factors (high weight, 0·99, 0·99–0·99); psoriasis of the palms and/or soles (0·75, 0·61–0·91); and presence of small plaques only compared with small and large plaques (0·78, 0·62–0·96). White ethnicity (1·48, 1·12–1·97) and higher baseline PASI (1·04, 1·03–1·04) were associated with increased odds of achieving PASI 90. The findings were largely consistent at 12 months. There was little evidence for predictors of differential treatment response. CONCLUSIONS: Psoriasis phenotype and potentially modifiable factors are associated with poor outcomes with biologics, underscoring the need for lifestyle management. Effect sizes suggest that these factors alone cannot inform treatment selection. |
format | Online Article Text |
id | pubmed-6519065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65190652019-05-21 Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study Warren, R.B. Marsden, A. Tomenson, B. Mason, K.J. Soliman, M.M. Burden, A.D. Reynolds, N.J. Stocken, D. Emsley, R. Griffiths, C.E.M. Smith, C. Br J Dermatol Original Articles BACKGROUND: Biologic therapies have revolutionized the treatment of moderate‐to‐severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. OBJECTIVES: To evaluate demographic, social and clinical factors that could be used to predict effectiveness and stratify response to biologic therapies in psoriasis. METHODS: Using a multicentre, observational, prospective pharmacovigilance study (BADBIR), we identified biologic‐naive patients starting biologics with outcome data at 6 (n = 3079) and 12 (n = 3110) months. Associations between 31 putative predictors and outcomes were investigated in univariate and multivariable regression analyses. Potential stratifiers of treatment response were investigated with statistical interactions. RESULTS: Eight factors associated with reduced odds of achieving ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90) at 6 months were identified (described as odds ratio and 95% confidence interval): demographic (female sex, 0·78, 0·66–0·93); social (unemployment, 0·67, 0·45–0·99); unemployment due to ill health (0·62, 0·48–0·82); ex‐ and current smoking (0·81, 0·66–0·99 and 0·79, 0·63–0·99, respectively); clinical factors (high weight, 0·99, 0·99–0·99); psoriasis of the palms and/or soles (0·75, 0·61–0·91); and presence of small plaques only compared with small and large plaques (0·78, 0·62–0·96). White ethnicity (1·48, 1·12–1·97) and higher baseline PASI (1·04, 1·03–1·04) were associated with increased odds of achieving PASI 90. The findings were largely consistent at 12 months. There was little evidence for predictors of differential treatment response. CONCLUSIONS: Psoriasis phenotype and potentially modifiable factors are associated with poor outcomes with biologics, underscoring the need for lifestyle management. Effect sizes suggest that these factors alone cannot inform treatment selection. John Wiley and Sons Inc. 2018-08-28 2019-05 /pmc/articles/PMC6519065/ /pubmed/30155885 http://dx.doi.org/10.1111/bjd.16776 Text en © 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Warren, R.B. Marsden, A. Tomenson, B. Mason, K.J. Soliman, M.M. Burden, A.D. Reynolds, N.J. Stocken, D. Emsley, R. Griffiths, C.E.M. Smith, C. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study |
title | Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study |
title_full | Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study |
title_fullStr | Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study |
title_full_unstemmed | Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study |
title_short | Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study |
title_sort | identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519065/ https://www.ncbi.nlm.nih.gov/pubmed/30155885 http://dx.doi.org/10.1111/bjd.16776 |
work_keys_str_mv | AT warrenrb identifyingdemographicsocialandclinicalpredictorsofbiologictherapyeffectivenessinpsoriasisamulticentrelongitudinalcohortstudy AT marsdena identifyingdemographicsocialandclinicalpredictorsofbiologictherapyeffectivenessinpsoriasisamulticentrelongitudinalcohortstudy AT tomensonb identifyingdemographicsocialandclinicalpredictorsofbiologictherapyeffectivenessinpsoriasisamulticentrelongitudinalcohortstudy AT masonkj identifyingdemographicsocialandclinicalpredictorsofbiologictherapyeffectivenessinpsoriasisamulticentrelongitudinalcohortstudy AT solimanmm identifyingdemographicsocialandclinicalpredictorsofbiologictherapyeffectivenessinpsoriasisamulticentrelongitudinalcohortstudy AT burdenad identifyingdemographicsocialandclinicalpredictorsofbiologictherapyeffectivenessinpsoriasisamulticentrelongitudinalcohortstudy AT reynoldsnj identifyingdemographicsocialandclinicalpredictorsofbiologictherapyeffectivenessinpsoriasisamulticentrelongitudinalcohortstudy AT stockend identifyingdemographicsocialandclinicalpredictorsofbiologictherapyeffectivenessinpsoriasisamulticentrelongitudinalcohortstudy AT emsleyr identifyingdemographicsocialandclinicalpredictorsofbiologictherapyeffectivenessinpsoriasisamulticentrelongitudinalcohortstudy AT griffithscem identifyingdemographicsocialandclinicalpredictorsofbiologictherapyeffectivenessinpsoriasisamulticentrelongitudinalcohortstudy AT smithc identifyingdemographicsocialandclinicalpredictorsofbiologictherapyeffectivenessinpsoriasisamulticentrelongitudinalcohortstudy AT identifyingdemographicsocialandclinicalpredictorsofbiologictherapyeffectivenessinpsoriasisamulticentrelongitudinalcohortstudy |